Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Durect Corp (DRRX)

Durect Corp (DRRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 309,272
  • Shares Outstanding, K 227,406
  • Annual Sales, $ 30,110 K
  • Annual Income, $ -580 K
  • 60-Month Beta 1.41
  • Price/Sales 10.42
  • Price/Cash Flow N/A
  • Price/Book 4.12
Trade DRRX with:

Options Overview

Details
  • Implied Volatility 539.30%
  • Historical Volatility 43.89%
  • IV Percentile 99%
  • IV Rank 91.77%
  • IV High 582.72% on 07/08/21
  • IV Low 55.14% on 08/18/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 325
  • Volume Avg (30-Day) 270
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 16,036
  • Open Int (30-Day) 25,227

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.04
  • Number of Estimates 3
  • High Estimate -0.04
  • Low Estimate -0.05
  • Prior Year 0.07
  • Growth Rate Est. (year over year) -157.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2800 +6.25%
on 07/19/21
1.8100 -24.86%
on 06/28/21
-0.4600 (-25.27%)
since 06/25/21
3-Month
1.2800 +6.25%
on 07/19/21
1.9300 -29.53%
on 05/03/21
-0.4700 (-25.68%)
since 04/27/21
52-Week
1.2800 +6.25%
on 07/19/21
2.9470 -53.85%
on 02/03/21
-0.7000 (-33.98%)
since 07/27/20

Most Recent Stories

More News
DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

/PRNewswire/ --  (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the market close on .

DRRX : 1.3600 (-1.45%)
DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit

/PRNewswire/ -- (Nasdaq: DRRX) today announced it will present at the , being held virtually July 13-15, 2021. 

DRRX : 1.3600 (-1.45%)
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027

ABT : 119.81 (+0.24%)
ACRX : 1.1900 (-1.65%)
ACOR : 3.96 (-7.69%)
AXSM : 52.66 (+1.68%)
BAYRY : 14.9200 (-1.33%)
BDRFF : 119.7000 (unch)
BDSI : 3.64 (+0.55%)
BMY : 67.49 (-0.30%)
COLL : 24.76 (+0.61%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3600 (-1.45%)
EGLT : 0.0315 (-63.37%)
LLY : 243.58 (+0.15%)
FLXN : 6.14 (-1.13%)
GLPG : 60.37 (+0.48%)
HRTX : 12.24 (-2.47%)
KMPH : 10.76 (+0.09%)
MRK : 77.85 (+0.79%)
MESO : 7.04 (-1.68%)
NKTR : 15.91 (-2.03%)
NVS : 91.32 (+0.40%)
ORXOY : 4.4499 (-1.55%)
PFE : 42.10 (+0.69%)
REGN : 581.01 (+0.56%)
VRX.TO : 30.80 (-3.33%)
DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)

/PRNewswire/ --  (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic...

DRRX : 1.3600 (-1.45%)
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)

/PRNewswire/ --  (Nasdaq: DRRX) today announced it will present two posters at the 2021 to be held virtually , 2021. 

DRRX : 1.3600 (-1.45%)
US Pain Relief Therapeutics Market Share 2021 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2027

The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ABT : 119.81 (+0.24%)
ACRX : 1.1900 (-1.65%)
ACOR : 3.96 (-7.69%)
AXSM : 52.66 (+1.68%)
BAYRY : 14.9200 (-1.33%)
BDRFF : 119.7000 (unch)
BDSI : 3.64 (+0.55%)
BMY : 67.49 (-0.30%)
COLL : 24.76 (+0.61%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3600 (-1.45%)
EGLT : 0.0315 (-63.37%)
LLY : 243.58 (+0.15%)
FLXN : 6.14 (-1.13%)
GLPG : 60.37 (+0.48%)
HRTX : 12.24 (-2.47%)
KMPH : 10.76 (+0.09%)
MRK : 77.85 (+0.79%)
MESO : 7.04 (-1.68%)
NKTR : 15.91 (-2.03%)
NVS : 91.32 (+0.40%)
ORXOY : 4.4499 (-1.55%)
PFE : 42.10 (+0.69%)
REGN : 581.01 (+0.56%)
VRX.TO : 30.80 (-3.33%)
Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -15.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

DRRX : 1.3600 (-1.45%)
Durect: Q1 Earnings Snapshot

CUPERTINO, Calif. (AP) _ Durect Corp. (DRRX) on Tuesday reported a loss of $10.1 million in its first quarter.

DRRX : 1.3600 (-1.45%)
DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs

, /PRNewswire/ --  (Nasdaq: DRRX) today announced financial results for the three months ended and provided a corporate update.

DRRX : 1.3600 (-1.45%)
DURECT Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 4, 2021 / DURECT Corp. (NASDAQ:DRRX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 4:30 PM Eastern Time....

DRRX : 1.3600 (-1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from...

See More

Key Turning Points

3rd Resistance Point 1.4567
2nd Resistance Point 1.4333
1st Resistance Point 1.3967
Last Price 1.3600
1st Support Level 1.3367
2nd Support Level 1.3133
3rd Support Level 1.2767

See More

52-Week High 2.9470
Fibonacci 61.8% 2.3102
Fibonacci 50% 2.1135
Fibonacci 38.2% 1.9168
Last Price 1.3600
52-Week Low 1.2800

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar